28345022|t|Ex Vivo Oncolytic Virotherapy with Myxoma Virus Arms Multiple Allogeneic Bone Marrow Transplant Leukocytes to Enhance Graft versus Tumor
28345022|a|Allogeneic stem cell transplant -derived T cells have the potential to seek and eliminate sites of residual cancer that escaped primary therapy. Oncolytic myxoma virus (MYXV) exhibits potent anti-cancer efficacy against human cancers like multiple myeloma (MM) and can arm transplant -derived T cells to become more effective cancer killers in vitro and in an immunodeficient xenotransplant murine model. Here, we tested ex vivo MYXV virotherapy against residual murine MM in immunocompetent mice using an allogeneic mouse-mouse model. In contrast to all human MM cell lines previously tested, the murine MM cell line tested here was highly resistant to direct MYXV infection and oncolysis in vitro. Despite this in vitro resistance, we found that ex vivo MYXV -armed allogeneic bone marrow (BM) transplantation dramatically ablated pre-seeded residual MM in vivo. Unexpectedly, we show that both neutrophils and activated T cells from the donor function as virus-armed carrier cells, and MYXV -preloaded cells enhanced MM killing. Our results demonstrate a novel therapeutic paradigm for residual cancer, in which multiple classes of allotransplant leukocytes can be armed by MYXV ex vivo to enhance the graft-versus-tumor effects.
28345022	8	29	Oncolytic Virotherapy	T058	UMLS:C1563738
28345022	35	47	Myxoma Virus	T005	UMLS:C0027150
28345022	62	95	Allogeneic Bone Marrow Transplant	T058	UMLS:C0398533
28345022	96	106	Leukocytes	T017	UMLS:C0023516
28345022	118	136	Graft versus Tumor	T038	UMLS:C0600555
28345022	137	168	Allogeneic stem cell transplant	T058	UMLS:C4255274
28345022	178	185	T cells	T017	UMLS:C0039194
28345022	236	251	residual cancer	T038	UMLS:C0242594
28345022	265	280	primary therapy	T058	UMLS:C1708063
28345022	292	304	myxoma virus	T005	UMLS:C0027150
28345022	306	310	MYXV	T005	UMLS:C0027150
28345022	328	339	anti-cancer	T103	UMLS:C0003392
28345022	340	348	efficacy	T062	UMLS:C1707887
28345022	357	362	human	T204	UMLS:C0086418
28345022	363	370	cancers	T038	UMLS:C0027651
28345022	376	392	multiple myeloma	T038	UMLS:C0026764
28345022	394	396	MM	T038	UMLS:C0026764
28345022	410	420	transplant	T058	UMLS:C0040732
28345022	430	437	T cells	T017	UMLS:C0039194
28345022	463	469	cancer	T038	UMLS:C0027651
28345022	470	477	killers	T038	UMLS:C1752435
28345022	566	570	MYXV	T005	UMLS:C0027150
28345022	571	582	virotherapy	T058	UMLS:C1563738
28345022	600	606	murine	T204	UMLS:C0025929
28345022	607	609	MM	T038	UMLS:C0026764
28345022	613	628	immunocompetent	T201	UMLS:C1512656
28345022	629	633	mice	T204	UMLS:C0025929
28345022	643	671	allogeneic mouse-mouse model	T038	UMLS:C2986594
28345022	692	711	human MM cell lines	T017	UMLS:C0682523
28345022	735	754	murine MM cell line	T017	UMLS:C1513528
28345022	798	802	MYXV	T005	UMLS:C0027150
28345022	803	812	infection	T038	UMLS:C3714514
28345022	817	826	oncolysis	T038	UMLS:C0333516
28345022	893	897	MYXV	T005	UMLS:C0027150
28345022	905	948	allogeneic bone marrow (BM) transplantation	T058	UMLS:C0149615
28345022	990	992	MM	T038	UMLS:C0026764
28345022	993	1000	in vivo	T082	UMLS:C1515655
28345022	1034	1045	neutrophils	T017	UMLS:C0027950
28345022	1060	1067	T cells	T017	UMLS:C0039194
28345022	1077	1091	donor function	T038	UMLS:C0007613
28345022	1095	1120	virus-armed carrier cells	T017	UMLS:C0007634
28345022	1126	1130	MYXV	T005	UMLS:C0027150
28345022	1142	1147	cells	T017	UMLS:C0007634
28345022	1157	1159	MM	T038	UMLS:C0026764
28345022	1160	1167	killing	T038	UMLS:C1752435
28345022	1226	1241	residual cancer	T038	UMLS:C0242594
28345022	1272	1286	allotransplant	T058	UMLS:C0040739
28345022	1287	1297	leukocytes	T017	UMLS:C0023516
28345022	1314	1318	MYXV	T005	UMLS:C0027150
28345022	1342	1368	graft-versus-tumor effects	T038	UMLS:C0600555